Fidelity Investments’s CureVac CVAC Stock Holding History

Fidelity Investments’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,600	Closed	-$4.43K	–	5357
2025 Q1	$4.43K	Buy	+1,600	New	+$5.57K	﹤0.01%	4736
2022 Q3	–	Sell	-2,557	Closed	-$35K	–	4927
2022 Q2	$35K	Sell	2,557 -181	-7%	-$2.99K	﹤0.01%	3688
2022 Q1	$54K	Buy	+2,738	New	+$54.7K	﹤0.01%	3656

Other funds holding CVAC

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Fidelity Investments's CVAC Position: Q2 2025 in Review

Fidelity Investments sold out of CureVac (CVAC) in Q2 2025, closing a stake of 1,600 shares — an estimated $4.43K sold.

Fidelity Investments first reported a position in CVAC in Q1 2022 and held it in 3 quarters. The position peaked at $54K in Q1 2022. 91 funds tracked by Wall St. Rank hold CVAC as of Q2 2025.

Fidelity Investments reported no remaining CureVac position as of Q2 2025 after selling out during the quarter.
Fidelity Investments sold 1,600 CureVac shares in Q2 2025, an estimated $4.43K.
Fidelity Investments first reported a position in CureVac in Q1 2022 and held it in 3 quarters.
Fidelity Investments's CureVac position peaked at $54K in Q1 2022.
91 funds tracked by Wall St. Rank held CureVac as of Q2 2025.

Based on Fidelity Investments's 13F filing for Q2 2025, filed 14 Aug 2025.